Fig. 6

TSP1 expression is downregulated and negatively correlates with EZH2 and NE markers in NEPC. a Expression of EZH2 and ENO2 is higher (P = 1.78E-11, P = 1.6E-3, respectively), while TSP1 expression is lower (P = 1.0E-9), in metastatic CRPCs than in untreated localized prostate cancers (Grasso_PCa). b Expression of EZH2 and ENO2 is higher (P = 2.95E-4, P = 1.4E-3, respectively), while TSP1 expression is lower (P = 0.017), in NEPC than in adenocarcinoma CRPCs (Beltran_NEPC). P values are from unpaired two-tailed Student’s t test. All values are mean ± standard deviation. ****P ≤ 0.0001. *P ≤ 0.05. c Negative correlation of TSP1 and EZH2 expression in the Grasso_PCa and Beltran_NEPC datasets. d The expression of NE marker CHGA is negatively and positively correlated with TSP1 and EZH2, respectively, in localized PCa and metastatic CRPC in Grasso_PCa data. In addition, EZH2 expression positively correlates with that of another NE marker TUBB3 in TCGA prostate cancer dataset. e Negative correlation of TSP1 and EZH2 expression in the 1000 Cancer Cell Line Encyclopedia (CCLE) dataset and TCGA breast cancer dataset. Spearman Correlation Coefficient Rho and associated P values were indicated for each scatter plots. Additional results from patient samples are in Supplementary Fig. 3 and 4